One channel, many dials
The GABA-A receptor is a ligand-gated ion channel: when GABA binds, a pore opens and chloride ions flow into the neuron, making it harder to fire. Both benzodiazepines and barbiturates don't replace GABA — they make this channel respond more strongly. They are allosteric modulators, binding their own sites and turning up the volume on GABA's natural effect. This whole family is grouped as sedative-hypnotics and, more broadly, CNS depressants.
Why benzodiazepines won and the safety margin
Because they amplify GABA only where GABA is already acting, benzodiazepines have a wide therapeutic index — the gap between a helpful dose and a lethal one is large. Barbiturates have a narrow one: the calming dose and the breathing-stopping dose sit uncomfortably close. That single fact is why benzodiazepines largely replaced barbiturates for anxiety and insomnia, and why barbiturates survive mostly in anaesthesia and a few seizure settings.
Benzodiazepines are useful anxiolytics short-term, but the brain adapts: with regular use the receptors down-regulate, the drug works less well, and stopping suddenly can trigger a dangerous withdrawal syndrome with rebound anxiety, insomnia, and even seizures. They are meant for brief courses or careful tapering, not indefinite use.
Reading a sedative dose
Doses are picked to land on a useful spot of the GABA dial. A small dose relieves anxiety while leaving you awake; a larger one brings sleep; a still larger one is used for anaesthesia or to abort a seizure. Knowing where on this ladder a given dose sits tells you what effect — and what risk — to expect.
GABA-A channel: GABA binds -> Cl- flows in -> neuron quieter Benzodiazepine: opens MORE OFTEN (only when GABA present) -> wide therapeutic index, ceiling on depression -> antidote: flumazenil Barbiturate: opens LONGER, and at high dose opens WITHOUT GABA -> narrow therapeutic index, no breathing ceiling -> no specific antidote Danger multiplies with other CNS depressants (e.g. alcohol, opioids)